(Q37902948)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Chronic lymphocytic leukemia: an update on biology and treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

0 references

1 reference

chronic lymphocytic leukemia

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

John C Riches

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

John G Gribben

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

379-385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21773694%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11912-011-0188-6

8 February 2020

exact match

0 references

cites work

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Regulation of B-cell fate by antigen-receptor signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Antigens in chronic lymphocytic leukemia--implications for cell origin and leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Acquired CD40-ligand deficiency in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0188-6

In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis

21 January 2018

1 reference

12 December 2020

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

1 reference

12 December 2020

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

1 reference

12 December 2020

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

1 reference

12 December 2020

CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes

1 reference

12 December 2020

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

1 reference

12 December 2020

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

1 reference

12 December 2020

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

Failure of B Cells of Chronic Lymphocytic Leukemia in Presenting Soluble and Alloantigens

1 reference

12 December 2020

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor

1 reference

12 December 2020

CD40 stimulation sensitizes CLL cells to rituximab-induced cell death

1 reference

12 December 2020

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

1 reference

12 December 2020

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

1 reference

12 December 2020